22 Aug 2017,
  • HSI:
    27,154.68 107.11 (0.40%)
    HSCI:
    10,751.54 57.89 (0.54%)
    HKSPLC25:
    34,826.82 74.89 (0.22%)
    HKSPGEM:
    267.03 0.26 (0.10%)
  • HSCEI:
    10,751.54 57.89 (0.54%)
    HSCCI:
    4,250.31 39.75 (0.94%)
    HSFML25:
    9,337.75 83.29 (0.90%)
    H-FIN:
    17,307.90 54.20 (0.31%)
  • Hang Seng Index
  • 27,154.68

  • 107.11 (0.40%)
HSCI 10,751.5 57.9
HKSPLC25 34,826.8 74.9
HKSPGEM 267.0 0.3
HSCEI 10,751.5 57.9
HSCCI 4,250.3 39.8
HSFML25 9,337.8 83.3
H-FIN 17,307.9 54.2
Stay Connected With EQS TodayIR

China Shineway Pharmaceutical Group Limited (02877.HK)

Pharmaceuticals

INTRADAY CHART

more

FINANCIAL REPORTSmore

2016 (AR)
2016 (IR)
2015 (AR)

PRESENTATIONSmore

  • Annual Result ...
    2017
  • Interim Resul ...
    2016
  • Annual Result ...
    2016
China Shineway Pharmaceutical Group Limited principally engages in the development, manufacture and sales of modern Chinese medicines. It is one of the "Top 100 pharmaceutical enterprises" and "Top 50 Chinese medicine enterprises" in China. The company's shares are listed on the Main Board of the Hong Kong Stock Exchange. China Shineway was ranked amongst the top 10 Chinese medicine manufacturers in 2004 based on comprehensive strength...
+ More Company Profile

LI Zhenjiang -

aged 61, is an executive Director and one of the founders of the Group. Mr. Li obtained an EMBA degree from the Yangtze Commercial Institute. Mr. Li joined the predecessor of the Group in 1974 and has been the Chairman and President of the Group and its predecessor since 1984 with responsibility for business development and strategy. He has more than 20 years’ experience in the operation and management of modern Chinese medicine enterprises. Mr. Li takes charge of the overall management of the Group and is also specifically responsible for the Group’s research and development activities. Mr. Li is a Representative to the 10th and 11th National People’s Congress. He was named as an Outstanding Entrepreneur in the PRC Pharmaceutical Industry in 1994 and has received a National Wu Yi Labour Award and special subsidies of the State Council. Mr. Li is the vice-chairman of the PRC Chinese Medicine Association. Mr. Li is also directors of several members of the Group. Mr. Li is the father of Ms. Lee Ching Ton Brandelyn, the executive Director.

XIN Yunxia -

aged 53, is an executive Director and one of the founders of the Group. Ms. Xin graduated from the Yangtze Commercial Institute with an EMBA degree. Ms. Xin is primarily responsible for the Group’s human resources management and operation. Ms. Xin joined the predecessor of the Group in 1981, focused on administration. She was the Deputy General Manager (human resources management) of Shineway Medical immediately prior to the corporate reorganisation in preparation of the listing of the Company in 2004. Ms. Xin has more than 20 years’ experience in business management in the industry with the Group.

LI Huimin -

aged 49, is an executive Director. He obtained an EMBA degree from Chinese University of Hong Kong in 2016. He is primarily responsible for the marketing and sales of the Group’s products and, since joining the predecessor of the Group in 1992, focused on sales and marketing. Immediately prior to the corporate reorganisation in preparation of the listing of the Company in 2004, Mr. Li was the sales and marketing manager of Shineway Medical. He has developed a deep understanding of sales management in the PRC Chinese medicine industry with more than 15 years’ experience. Mr. Li is a vice-chairman of Hong Kong Chinese Prepared Medicine Traders Association since 2010.

LEE Ching Ton Brandelyn -

aged 34, is an executive Director appointed in 2012. She has studied in the United Kingdom and Australia, majoring in business administration. Ms. Lee has solid knowledge in finance principles. Ms. Lee has worked in areas relating to corporate development in the Company, thus has accumulated a definite amount of administration and management experience. She has been the Company’s Executive Assistant since August 2010. Ms. Lee is the daughter of Mr. Li Zhenjiang, the chairman and the executive Director.

CHEN Zhong -

aged 50, is an executive Director appointed on 1 December 2014. He is qualified as a chief senior engineer and is a certified pharmacist. He graduated from Hebei Medical University in 1990 with a bachelor’s degree in pharmacy. Mr. Chen is a leader of Modern Traditional Chinese Medicines Manufacturing Technology of Hebei Province, chief officer of the National and Local United Engineering Laboratory for the Development Technology of New Chinese Medicine Injection, chief officer of Chinese Medicine Injection Engineering and Technology Research Centre in Hebei Province, general vice-officer of National-Recognition on Enterprise Technology Centre, deputy officer of specialized committee of traditional Chinese medicines on economic in China Association of Traditional Chinese Medicine and price review expert on medicines in National Development and Reform Commission of the People’s Republic of China. Mr. Chen joined the predecessor of the group in 1990 and is currently the vice president of the Shineway Pharmaceutical Group Limited (formerly known as Shineway Pharmaceutical Company Limited) (“Shineway Pharmaceutical”), director of Hebei Shineway Pharmaceutical Company Limited (“Hebei Shineway”), director of Xizang Shineway Pharmaceutical Company Limited and director of Shineway Pharmaceutical (Hainan) Company Limited. He is responsible for quality control on production and technology management activities of the Company’s group with over 20 years of experience.

CHENG Li -

aged 57, was appointed as an independent non-executive Director in 2006. She has a legal science bachelor’s degree and the legal science master’s degree from the law department of Japan Special Training University. She also studied in Sino-Japanese Investment Trade Promotion Association. She joined Commerce & Finance Law Office in 1995 and became a partner of Commerce & Finance Law Office since 2002. She is currently a member of Beijing Lawyer Association.

SUN Liutai -

aged 53, was appointed as an independent non-executive Director in 2010. He has studied postgraduate programme in Economic Management Institute of North Western University. Mr. Sun has sound experience in accounting profession and finance. In 2003, he was appointed by Hebei Securities and Futures Commission to investigate a company listed on Shenzhen Stock Exchange. He worked as an assistant manager of general strategic department in China Investment Bank Hebei branch from 1987 to 1992, and worked as an assistant general manager in a Hebei Investment Management Consultancy Company in 1992 to 1995. He then worked as aprincipal accountant in Hebei Yongzhengde Certified Public Accountants from 1995 to 2002, during which he was engaged in audit of a company listed on the Shanghai Stock Exchange. Mr. Sun was appointed as a partner of Hebei Peking Certified Public Accountants from 2002 to present. Mr. Sun was a general committee of Hebei Society of Certified Public Accountants in 2002 to 2008, and was employed as an independent director and audit in-charge of Qinhuangdao Yaohua Glass Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600716) from May 2002 to June 2008. He is a Chinese Certified Public Accountant.

LUO Guoan -

aged 70, graduated with biochemical engineering profession, and subsequently obtained master degree in chemistry from East China University of Science and Technology. Prof. Luo is the head of the Collaboration Centre of Network for Traditional Chinese Medicine of National Education Ministry, professor and doctoral tutor of Department of Chemistry in Tsinghua University. Prof. Luo is currently the committee chairman of the biopharmaceutical technology branch of China Medicinal Biotech Association, council chairman of the National Conference on Pharmaceutical Analysis and the chairman of Chinese Medicine Product Development and Cultivation of Professional Committee in China Association of Traditional Chinese Medicine. Prof. Luo is a well-known expert in the field of Chinese medicine analysis and quality control. He has long been engaged in drug analysis and traditional Chinese medicine systems and biological research. He has published a book titled “Systems Biology for Traditional Chinese Medicine” which is an international publication of traditional Chinese medicine system biology monographs.

WANG Zheng Pin -

aged 63, was an executive Director appointed in 2013 and resigned on 1 January 2016. Following his resignation, he continues to provide service to the Company as senior management. He is a United States citizen. He obtained doctor’s degree in China and attended postdoctoral training in Biochemistry in the United States. He has 20 years of experience in research on traditional Chinese medicine, around 15 years of experience in research and industrialized pharmaceutical products, and 8 years of teaching experience in university. He has served as chief scientific officer in a pharmaceutical company in China, and has also served as a chief technology officer in an American biopharmaceutical company. He has solid knowledge and skills on pharmaceutical product development. He has joined the Company as Chief Scientific Officer since May 2013.

LUK Yat Hung -

aged 58, is the head of investor relation of the Group. Mr. Luk is a fellow member of both Chartered Association of Certified Accountants of the United Kingdom and Hong Kong Institute of Certified Public Accountants with a master’s degree in business administration with Oklahoma City University and a Hong Kong Securities Institute Specialist Certificate in corporate finance. Prior to joining the Group, Mr. Luk served in a number of international conglomerates and listed groups as chief financial officer and executive director responsible for corporate finance, investor relations and corporate communication. Mr. Luk joined the Group in 2010. Mr. Luk is responsible for the Group’s investor relations and corporate communication.

LEE Bun Ching, Terence -

aged 44, is the Financial Controller and Company Secretary of the Group. Mr. Lee is a member of the Hong Kong Institute of Certified Public Accountants and American Institute of Certified Public Accountants. He holds a bachelor’s degree in Accounting and Financial Analysis and a master’s degree in Economics and Finance from the University of Warwick in the United Kingdom. Mr. Lee has extensive work experience in the field of auditing, accounting, finance and taxation. Prior to joining the Group, he served as the Group Accounting Controller of a listed company in Hong Kong for over 3 years. Between 1996 and 2007, Mr. Lee worked in a reputable international accounting firm and was a Senior Manager when he left in 2007. He joined the Group in 2011.

Audit Committee
Composition
Mr. SUN Liutai (Chairman)
Ms. CHENG Li
Professor LUO Guoan
 
Remuneration Committee
Composition
Ms. CHENG Li (Chairman)
Ms. XIN Yunxia
Mr. SUN Liutai
 
Nomination Committee
Composition
Mr. LI Zhenjiang (Chairman)
Mr. SUN Liutai
Professor LUO Guoan
 
Procedures for Shareholders to Propose a Person for Election As a Director
 
Memorandum and Articles of Association
 
Code for Securities Transactions by Relevant Employees
 
Whistleblowing Policy
 
Policy on Disclosure of Inside Information
 

UPCOMING EVENT

S M T W T F S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

COMPANY INFORMATION

Listed Date 02 Dec 2004

Address Suite 3109, 31/F.,
Central Plaza,18 Harbour Road,
Wanchai, Hong Kong

Telephone (852) 3521-0816

Facsimile (852) 3521-0821

Email MetLuk@shineway.com.hk

No. of Click Rate

156213